Fresh Tracks Therapeutics, Inc. (FRTX)
| Market Cap | 5.59M |
| Revenue (ttm) | 8.01M |
| Net Income (ttm) | -5.69M |
| Shares Out | 5.97M |
| EPS (ttm) | -1.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,162 |
| Average Volume | 1,832 |
| Open | 0.9400 |
| Previous Close | 0.9350 |
| Day's Range | 0.9350 - 0.9400 |
| 52-Week Range | 0.0300 - 1.0300 |
| Beta | 1.17 |
| RSI | 73.74 |
| Earnings Date | Mar 14, 2025 |
About Fresh Tracks Therapeutics
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. [Read more]
Financial Performance
In 2023, Fresh Tracks Therapeutics's revenue was $8.01 million, an increase of 15.31% compared to the previous year's $6.94 million. Losses were -$5.69 million, -73.02% less than in 2022.
Financial StatementsNews
Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market
BOULDER, Colo. , Feb. 25, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolu...
Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution
BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("t...
Fresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of Company
BOULDER, Colo. , Dec. 6, 2024 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) ("Fresh Tracks" or "the Company") announced today that a Scheduling Order has been issued by the Court of...
Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court Company filed an answer in overall agreement with petition on Jun...
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024
Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th
New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, wh...
Fresh Tracks Therapeutics Announces Listing on OTC Pink Market
BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) (“Fresh Tracks” or the “Company”) announced today that the Company's common stock was suspended from ...
Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th
Common stock expected to begin trading on over-the-counter market following suspension Common stock expected to begin trading on over-the-counter market following suspension
Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders
Meeting adjourned to December 27, 2023 at 10 a.m. MT
Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders
Meeting adjourned to December 15, 2023 at 10 a.m. MT
Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m.
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution I...
Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution
Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of th...
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromi...
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value Strengthens cash position as Company continues to evaluate strategic options to maximize shar...
Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023
Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for at...
Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02
FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study's primary objectives
Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer
Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the Company Rob Brown to continue serving as a member of the Board of Directors and as a special advisor...
Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity
Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023 Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023
Fresh Tracks Therapeutics, Inc. (FRTX) Q3 2022 Earnings Call Transcript
Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Garth Russell - LifeSci Advisors Robert Brown - CEO Monica Luchi - Chi...
Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Phase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disru...
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing